Clinical Study
No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma
Table 2
Univariate analysis of CR, OS and DFS for 107 patients treated at Songklanagarind hospital.
| Variables | Total | Univariate analysis | CR no. (%) | OS HR (95% CI) | DFS HR (95% CI) |
| Age group, y | | | | | ≤60 | | 45 (68.2) | 1.0 | 1.0 | >60 | | 26 (63.4) | 1.4 (0.9–2.4) | 1.2 (0.6–2.5) | Sex | | | | | Male | | 39 (70.9) | 1.0 | 1.0 | Female | | 32 (61.5) | 1.1 (0.6–1.8) | 0.9 (0.4–1.8) | Stage | | | | | II | | 35 (72.9) | 1.0 | 1.0 | III | | 18 (64.3) | 2.0 (1.1–3.7) | 3.2 (1.3–7.7) | IV | | 18 (58.1) | 2.1 (1.1–3.9)* | 2.5 (1.0–6.3)* | B symptoms | | | | | Absent | | 45 (72.6) | 1.0 | 1.0 | Present | | 26 (57.8) | 1.9 (1.1–3.1)* | 2.6 (1.2–5.4)* | Bulky mass | | | | | Absent | | 59 (72.0) | 1.0 | 1.0 | Present | | 12 (48.0)* | 2.0 (1.1–3.6)* | 0.5 (0.1–1.9) | Extranodal | | | | | Absent | | 30 (75.0) | 1.0 | 1.0 | Present | | 41 (61.2) | 1.5 (0.9–2.7) | 1.4 (0.7–3.0) | LDH | | | | | Normal | | 34 (77.3) | 1.0 | 1.0 | High | | 37 (58.7) | 1.9 (1.1–3.3)* | 2.4 (1.1–5.2)* | PS | | | | | 0-1 | | 66 (79.5) | 1.0 | 1.0 | 2–4 | | 5 (20.8)** | 4.8 (2.7–8.3)** | 1.5 (0.4–4.8) | p53 | | | | | 0–(2+) | | 36 (72) | 1.0 | 1.0 | 3+ | | 35 (61.4) | 1.2 (0.7–2.0) | 0.9 (0.4–1.9) | IPI | | | | | Low | | 20 (87.0) | 1.0 | 1.0 | Low Int. | | 29 (78.4) | 1.5 (0.6–3.4) | 1.2 (0.4–3.6) | High Int. | | 16 (57.1) | 3.6 (1.6–8.2) | 3.3 (1.1–9.7) | High | | 6 (31.6)** | 5.3 (2.2–12.6)** | 3.4 (0.9–13.0)* |
|
|
*
, **.
|